Attempts to enhance cell-mediated lysis of human leukaemia cells initially focused on the effector cells, using in vitro stimulation techniques with irradiated leukaemia cells, allogeneic cells or interferon (IFN) (Khare et al., 1980; Moore et al., 1982; Lee & Oliver, 1978; Pattengale et al., 1982; Taylor, 1981; Zarling et al., 1976; 1978; . Recent studies with various drugs including cytostatics (Schlager & Ohanian, 1979; Schlager, 1982; Collins, 1981; Kunkel & Welsh, 1981) demonstrated that treatment of the tumour targets can modulate their susceptibility to lysis.
Schlager and Ohanian (1979) reported on enhanced complement-dependent lysis induced by Actinomycin D in a guinea pig hepatoma (Schlager & Ohanian, 1979) and an enhanced T cell-mediated lysis induced by mitomycin C treatment of P815 mouse tumour cells (Schlager, 1982) .
Further, murine fibroblasts are minimally or not at all lysed by NK cells. Treatment of the fibroblasts with cycloheximide or Actinomycin D, however, induces strong NK cell mediated lysis. (Collins et al., 1981; Kunkel & Welsh, 1981) . In vitro derived carcinogen-transformed fibroblasts were highly NK sensitive, but again became resistant when passaged in mice with high NK cell activity (Collins et al., 1981) .
Therefore, we wondered whether freshly explanted human leukaemia cells might exhibit a resistance to NK cell-mediated lysis that could be overcome by drug treatment of the tumour cells. In fact, our data show that NK cell-mediated lysis of fresh human leukaemia cells is enhanced by treatment with Actinomycin D in addition to the enhancement that occurs with IFN treatment of effector cells.
Materials and methods

Cells
Peripheral blood from patients with acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC) was (New England Nuclear, Dreieich, FRG) was added. During the 1.5-2 h period of labelling the cells were resuspended every 20 min. The targets were washed x4 and adjusted to 105 cellsml-'. The total time of drug treatment was 2h pretreatment plus the labelling time.
Chromium release assay One hundred p1 effector cells (2.5-10 x 106 cells and serial dilutions) were mixed with 100 p1 of the target cell suspension in U-bottom microtiter plates in triplicate. After centrifugation at 50 g for 5 min, plates were incubated for 5.5 h. Chromium release was determined by counting 100 p1 supernatant aliquots in a y-counter. For spontaneous release target cells were incubated with medium alone, for total release with 5% Triton-x-100. Specific release was calculated according to the formula experimental release-spontaneous release 100 total release-spontaneous release IFN and ActD, respectively, resulted in greater lysis than obtained with either treatment alone, e.g., 55.2% for IFN pretreatment, 59.0% for ActD pretreatment and 83.2% for both IFN and ActD pretreatment in Expt. 1. Similar results were seen in the other experiments with the same target (Expts. 2 and 3) and with 2 other leukaemias (Expts. 7 and 11). These findings suggest that ActD renders an additional fraction of the leukaemia cells susceptible to NK lysis, a fraction that is not lysed within the time limits of the assay when IFN activated NK cells are used. Thus the percentage of fresh human leukaemia cells that can be lysed by spontaneously cytotoxic cells is higher than previously found. In all further experiments we primarily used IFN pretreatment of effector cells to obtain high specific release.
Representative experiments with the leukaemia cells of 4 donors using IFN-activated killer cells are shown in Figure 1 giving specific release at different E:T ratios. For the Vg target ( Figure IA ) IFN treatment of effector cells alone resulted in a The doses found suitable for enhancement of NK cell-mediated lysis of fresh human leukaemia cells were lower than the ActD concentrations of 40 pg ml-1 used by Schlager et al. (1979) for enhanced complement-dependent lysis of a guinea pig hepatoma, but they are comparable to the lugml-l dose used by Kunkel et al. (1981) for the enhancement of NK cell-mediated lysis of murine fibroblasts.
The same investigators employed longer drug pretreatment times of 17-24h. In our hands, overnight exposure as tested with the Vg target, reduced the spontaneous release, e.g. from 36 to 20% (data not shown) and made the comparison of treated and untreated leukaemia cells difficult. Therefore, we worked throughout the study with a standard treatment time of 3.5-4h, a procedure that did not result in a change of spontaneous release from the targets. For the 6 leukaemia targets resistant to the susceptibility enhancement by ActD, however, both longer periods of drug treatment and higher doses of ActD might have been effective.
In the 4 leukaemias without any lysis it is unlikely that the activity of the effector cells was insufficient, as the IFN-activated PBM assayed in parallel against K562 targets showed high activity in these experiments with the specific release always exceeding 50%. In addition effector cells from donor Jo, operative in experiments where enhancement of lysis was seen, were used in several of these "negative" experiments. Still, we cannot exclude that effector cells from other donors would have been able to mediate an enhanced lysis due to ActD treatment of the target cells since lysis of fresh leukaemia cells by IFN-activated effectors has been shown to depend on the effector-target combination (Moore et al., 1982) .
We then asked whether lysis of highly NK susceptible leukaemia cell lines could be further enhanced by ActD pretreatment. In 3 independent experiments (28, 29 and 30, Table I) K562 cells or Molt4 cells treated with various doses according to the established regime, did not show an enhancement but a dose-dependent decrease of lysability. One might speculate that in vitro cell lines cannot be enhanced in their susceptibility, because, they are already maximally lysed, while in vivo grown tumour cells, under the selective pressure of NK cells, become resistant and after drug exposure are susceptible to lysis again. This theory would be in keeping with the finding of Collins et al. (1981) , who found that in vitro cell lines with high susceptibility to NK cells became resistant after in vivo passage.
Additional control targets in our study were PBM and PHA-blasts (Expt. 23-27, Table I ).
Under optimized conditions we were unable to induce any lysis by ActD pretreatment of these normal lymphocytes and lymphoblasts. Thus, the enhancement of NK lysis by ActD appears to be restricted to malignant cells. In initial experiments we found that effector cells non-adherent to nylon wool can mediate enhanced lysis (data not shown), indicating that the killers are not monocytes. For further analysis we employed cold target inhibition experiments with radio-labelled ActD treated Vg, St and Ri leukaemia cells as targets and ActD-treated fresh leukaemia cells, NK sensitive Molt4 and K562 cells and NK-insensitive P815 cells as unlabelled inhibitors, together with IFN-treated effector cells. As shown in Figure 3A inhibition of lysis of ActDtreated Vg leukaemia cells was most pronounced with Molt4 cells, followed by the ActD-treated fresh leukaemia. P815, the NK insensitive mouse cell line, exerted slight inhibition in this experiment at the highest inhibitor-to-target ratio, consistent with a low level of lysis (13.3% at E:T 50:1) obtained with radio-labeled P815 in the same experiment. In a second experiment ( Figure 3B) , where K562 cells instead of Molt4 were used as inhibitors along with the ActD-treated Vg cells, essentially identical results were obtained, with K562 being superior as an inhibitor to ActDtreated Vg cells. Cold target inhibition experiments with ActD-treated radiolabelled St and Ri cells as targets gave the same type of result. Thus the NKsensitive leukaemia cell line cells and ActD-treated fresh leukaemia cells share target structures and are lysed by essentially one type of natural killer cell. This interpretation is consistent with our recent studies using monoclonal antibodies against NK cells (Ziegler-Heitbrock et al., in preparation) . Our observations with fresh human leukaemia cells demonstrate that susceptibility to NK cell-mediated lysis of a given target is not a constant property, but can be readily changed by exposure of the leukaemia cells to ActD. Working with cell lines, both Gidlund et al. (1981) and Clark et al. (1981) showed that susceptibility to NK lysis decreased or increased, when they were treated with inducers of cell differentiation. Induction of differentiation in the fresh leukaemic cells studied in this report, is an unlikely explanation for the observed enhancement since 4 hours are enough for these leukaemias while days of exposure were used in the differentiation induction experiments. At the molecular level, Figure 3A ) and 38.9% and 53.0% ( Figure 3B ) for the untreated and the ActD-treated Vg cells, respectively. Specific release from P815 targets as assessed in the same experiments was 13.3% and 16.9% at E:T ratio of 50:1 in the respective experiments. Schlager (1982) 
